Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Myriad Equity

  • Analysis & Opinion

Myriad Equity 's Opinion & Analysis
A complete archive of Myriad Equity 's articles, including current analysis & opinion.

In our previous article (link) on Unilife (UNIS), published on November 27th 2013, we predicted that UNIS would probably break 100% in YTD gains. After the company announced on December 2nd (link)...
It hasn’t been a good year for short sellers betting against the rapidly growing healthcare conglomerate OPKO Health (OPK) and its CEO/Chairman – Dr. Phillip Frost. Since the start of the year, OPK...
One of the biotechs of 2013 that continues to hold its ground is Ohr Pharmaceutical (OHRP) – a company that is best known for its Squalamine eye drops which are being developed as a treatment for wet...
Note: In addition to my regular discussion on select companies in the life science (“applied biology”) space, I’ve included a top-down discussion and exemplification of my main categorization method....
Background on the Complete Response Letter This note focuses on the implications of the complete response letter (CRL) received by Alimera (ALIM) for Iluvien. This product was developed by pSivida...
This article presumes that the reader is familiar with the general situation of Amarin Corporation (AMRN) and its drug Vascepa ahead of the ANCHOR Advisory Committee meeting and PDUFA goal date. We’ve...
Putting Malaria Vaccine Results in Perspective for Agenus Glaxo (GSK) has just released interim (18 month) results on its Phase III trial conducted in sub-Saharan Africa for its malaria vaccine,...
Investment Scenarios: The Positive and Negative Case pSivida (PSDV) has a very important binary event upcoming on October 17, 2013; this is the PDUFA date for Iluvien, an ocular implant for diabetic...
Despite some easing of the hyper-bullish sentiment in the currently bloated specialty pharmaceuticals sector, Aegerion Pharmaceuticals (AEGR) looks ready to finally breach the psychological $100/share...
Brain cancers are among the most deadly and hard-to-treat types of cancer in existence. Roughly 12,000 to 14,000 people in the United States alone have primary malignancies in the brain and nervous...